Inflammatory diseases, whether caused by excessive stress on certain tissues/parts of the body or arising from infections accompanying autoimmune or secondary diseases, have become a problem, especially in the Western world today. Whether these are inflammations of visceral organs, joints, bones, or the like, they are always a physiological reaction of the body, which always tries to eradicate noxious agents and restore tissue homeostasis. Unfortunately, this often results in damage, often irreversible, to the affected tissues. Nevertheless, these inflammatory reactions of the body are the results of excessive stress, strain, and the generally unhealthy environment, in which the people of Western civilization live. The pathophysiology and pathobiochemistry of inflammatory/autoimmune processes are being studied in deep detail, and pharmaceutical companies are constantly developing new drugs that modulate/suppress inflammatory responses and endogenous pro-inflammatory agents. In addition to new specifically targeted drugs for a variety of pro-inflammatory agents, a strategy can be found for the use of older drugs, which are formulated into special nanodrug delivery systems with targeted distribution and often modified release. This contribution summarizes the current state of research and development of nanoformulated anti-inflammatory agents from both conventional drug classes and experimental drugs or dietary supplements used to alleviate inflammatory reactions.

Centre ENET CEET VSB Technical University of Ostrava 17 listopadu 2172 15 708 00 Ostrava Poruba Czech Republic

Department of Analytical Chemistry Faculty of Natural Sciences Comenius University Ilkovicova 6 842 15 Bratislava Slovakia

Division of Biologically Active Complexes and Molecular Magnets Regional Centre of Advanced Technologies and Materials Czech Advanced Technology and Research Institute Palacky University Slechtitelu 27 783 71 Olomouc Czech Republic

Nanotechnology Centre CEET VSB Technical University of Ostrava 17 listopadu 2172 15 708 00 Ostrava Poruba Czech Republic

Zobrazit více v PubMed

Pahwa R., Goyal A., Bansal P., Jialal I. Chronic Inflammation. StatPearls Publishing; Tampa, FL, USA: 2019. [(accessed on 27 November 2020)]. Available online: https://www.ncbi.nlm.nih.gov/books/NBK493173.

Oxford University Hospitals NHS Foundation Trust Inflammatory Diseases. [(accessed on 27 November 2020)];2020 Available online: https://www.ouh.nhs.uk/oxparc/information/diagnoses/inflammatory-diseases.aspx.

Tsai D.H., Riediker M., Berchet A., Paccaud F., Waeber G., Vollenweider P., Bochud M. Effects of short- and long-term exposures to particulate matter on inflammatory marker levels in the general population. Environ. Sci. Pollut. Res. Int. 2019;26:19697–19704. doi: 10.1007/s11356-019-05194-y. PubMed DOI

Barcelos I.P., Troxell R.M., Graves J.S. Mitochondrial dysfunction and multiple sclerosis. Biology. 2019;8:37. doi: 10.3390/biology8020037. PubMed DOI PMC

Deepak P., Axelrad J.E., Ananthakrishnan A.N. The role of the radiologist in determining disease severity in inflammatory bowel diseases. Gastrointest. Endosc. Clin. N. Am. 2019;29:447–470. doi: 10.1016/j.giec.2019.02.006. PubMed DOI

Pfizer Inc. Chronic Inflammation and Inflammatory Disease. [(accessed on 27 November 2020)];2017 Available online: https://www.pfizer.com/news/featured_stories/featured_stories_detail/chronic_inflammation_and_inflammatory_disease.

National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention Inflammatory Bowel Disease Prevalence. [(accessed on 27 November 2020)]; Available online: https://www.cdc.gov/ibd/data-statistics.htm.

Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, USA Arthritis-Related Statistics. [(accessed on 27 November 2020)]; Available online: https://www.cdc.gov/arthritis/data_statistics/arthritis-related-stats.htm.

Smolen J.S., Aletaha D., McInnes I.B. Rheumatoid arthritis. Lancet. 2016;388:2023–2038. doi: 10.1016/S0140-6736(16)30173-8. PubMed DOI

Thakur S., Riyaz B., Patil A., Kaur A., Kapoor B., Mishra V. Novel drug delivery systems for NSAIDs in management of rheumatoid arthritis: An overview. Biomed. Pharmacother. 2018;106:1011–1023. doi: 10.1016/j.biopha.2018.07.027. PubMed DOI

Kotyla P.J., Islam M.A., Engelmann M. Clinical aspects of janus kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis. Int. J. Mol. Sci. 2020;21:7390. doi: 10.3390/ijms21197390. PubMed DOI PMC

Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428–435. doi: 10.1038/nature07201. PubMed DOI

Serhan C.N., Ward P.A. Molecular and Cellular Basis of Inflammation. Humana Press Inc.; Totowa, NJ, USA: 2010.

Malone S. Inflamed: Discover the Root Cause of Inflammation and Personalize a Step-By-Step Plan to Create a Healthy, Vibrant Life. Augustin Publishing; Locust Valley, NY, USA: 2016.

Diegelmann R.F. Basic Biology and Clinical Aspects of Inflammation. Bentham Science Publishers; Sharjah, UAE: 2016. (Book Series). Frontiers in Inflammation.

Ley K. Inflammation—Fundamental Mechanisms. La Jolla Institute for Allergy and Immunology; San Diego, CA, USA: 2018.

Cavaillon J.M., Singer M. Inflammation: From Molecular and Cellular Mechanisms to the Clinic. Wiley-VCH; Weinheim, Germany: 2018.

Coico R., Sunshine G. Immunology: A Short Course. 7th ed. Wiley-Blackwell; Chichester, UK: 2015.

Miyasaka M., Takatsu K. Chronic Inflammation: Mechanisms and Regulation. Springer; Tokyo, Japan: 2016.

Chang W.C., Chang W.C. Chronic Inflammation: Causes, Treatment Options and Role in Disease (Immunology and Immune System Disorders) Nova Biomedical; Hauppauge, NY, USA: 2013.

Van Dyke T.E., van Winkelhoff A.J. Infection and inflammatory mechanisms. J. Clin. Periodontol. 2013;40:1–7. doi: 10.1111/jcpe.12088. PubMed DOI

Earl C.S., An S.Q., Ryan R.P. The changing face of asthma and its relation with microbes. Trends Microbiol. 2015;23:408–418. doi: 10.1016/j.tim.2015.03.005. PubMed DOI PMC

Dulek D.E., Stokes Peebles R. Bacteria and asthma—more than we thought. Expert Rev. Respir. Med. 2011;5:329–332. doi: 10.1586/ers.11.33. PubMed DOI PMC

Mikhail I., Grayson M.H. Asthma and viral infections: An intricate relationship. Ann. Allergy Asthma Immunol. 2019;123:352–358. doi: 10.1016/j.anai.2019.06.020. PubMed DOI PMC

Sreenivasan P.K., Gaffar A. Antibacterials as anti-inflammatory agents: Dual action agents for oral health. Antonie Van Leeuwenhoek. 2008;93:227–239. doi: 10.1007/s10482-007-9197-8. PubMed DOI

Qiu C.C., Caricchio R., Gallucci S. Triggers of autoimmunity: The role of bacterial infections in the extracellular exposure of lupus nuclear autoantigens. Front. Immunol. 2019;10:2608. doi: 10.3389/fimmu.2019.02608. PubMed DOI PMC

Van Elsland D., Neefjes J. Bacterial infections and cancer. EMBO Rep. 2018;19:46632. doi: 10.15252/embr.201846632. PubMed DOI PMC

Chen L., Deng H., Cui H., Fang J., Zuo Z., Deng J., Li Y., Wang X., Zhao L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017;9:7204–7218. doi: 10.18632/oncotarget.23208. PubMed DOI PMC

Gautam C.S., Saha L. Fixed dose drug combinations (FDCs): Rational or irrational: A view point. Br. J. Clin. Pharmacol. 2008;65:795–796. doi: 10.1111/j.1365-2125.2007.03089.x. PubMed DOI PMC

Godman B., McCabe H., Leong T.D., Mueller D., Martin A.P., Hoxha I., Mwita J.C., Mutashambara Rwegereran G., Massele A., de Oliveira Costa J., et al. Fixed dose drug combinations—are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Rev. Pharmacoecon. Outcomes Res. 2020;20:1–26. doi: 10.1080/14737167.2020.1734456. PubMed DOI

Cernikova A., Jampilek J. Structure modification of drugs influencing their bioavailability and therapeutic effect. Chem. Listy. 2014;108:7–16.

Serhan C.N. Treating inflammation and infection in the 21st century: New hints from decoding resolution mediators and mechanisms. FASEB J. 2017;31:1273–1288. doi: 10.1096/fj.201601222R. PubMed DOI PMC

Vasaikar S., Bhatia P., Bhatia P.G., Yaiw K.C. Complementary approaches to existing target based drug discovery for identifying novel drug targets. Biomedicines. 2016;4:27. doi: 10.3390/biomedicines4040027. PubMed DOI PMC

Ul Islam N., Amin R., Shahid M., Amin M., Zaib S., Iqbal J. A multi-target therapeutic potential of Prunus domestica gum stabilized nanoparticles exhibited prospective anticancer, antibacterial, urease-inhibition, anti-inflammatory and analgesic properties. BMC Complement. Altern. Med. 2017;17:276. doi: 10.1186/s12906-017-1791-3. PubMed DOI PMC

Brullo C., Massa M., Rapetti F., Alfei S., Bertolotto M.B., Montecucco F., Signorello M.G., Bruno O. New hybrid pyrazole and imidazopyrazole antinflammatory agents able to reduce ROS production in different biological targets. Molecules. 2020;25:899. doi: 10.3390/molecules25040899. PubMed DOI PMC

Ramsay R.R., Popovic-Nikolic M.R., Nikolic K., Uliassi E., Bolognesi M.L. A perspective on multi-target drug discovery and design for complex diseases. Clin. Transl. Med. 2018;7:3. doi: 10.1186/s40169-017-0181-2. PubMed DOI PMC

Bolognesi M.L. Polypharmacology in a single drug: Multitarget drugs. Curr. Med. Chem. 2013;20:1639–1645. doi: 10.2174/0929867311320130004. PubMed DOI

Talevi A. Multi-target pharmacology: Possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective. Front. Pharmacol. 2015;6:205. doi: 10.3389/fphar.2015.00205. PubMed DOI PMC

Brase S. Privileged Scaffolds in Medicinal Chemistry: Design, Synthesis, Evaluation. Royal Society of Chemistry; Cambridge, UK: 2016.

Zhang W., Zhao Y., Zhang F., Wang Q., Li T., Liu Z., Wang J., Qin Y., Zhang X., Yan X., et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin. Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393. PubMed DOI PMC

Lemke T.L., Williams D.A. Foye’s Principles of Medicinal Chemistry. 7th ed. Lippincott Williams & Wilkins and Wolters Kluwer; Baltimore, MD, USA: 2013.

Jampilek J., Dolezal M., Opletalova V., Hartl J. 5-Lipoxygenase, leukotrienes biosynthesis and potential antileukotrienic agents. Curr. Med. Chem. 2006;13:117–129. doi: 10.2174/092986706775197935. PubMed DOI

Trevor A.J., Katzung B.G., Kruidering-Hall M. Katzung & Trevor’s Pharmacology. 12th ed. McGraw-Hill; New York, NY, USA: 2019.

Whalen K., Radhakrishnan R., Field C. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Wolters Kluwer; Philadelphia, PA, USA: 2019.

Psoriasis—Mayo Clinic. [(accessed on 27 November 2020)];2020 Available online: https://www.mayoclinic.org/diseases-conditions/psoriasis/diagnosis-treatment/drc-20355845.

Kushkevych I., Kollar P., Ferreira A.L., Palma D., Duarte A., Lopes M.M., Bartos M., Pauk K., Imramovsky A., Jampilek J. Antimicrobial effect of salicylamide derivatives against intestinal sulfate-reducing bacteria. J. Appl. Biomed. 2016;14:125–130. doi: 10.1016/j.jab.2016.01.005. DOI

Jampilek J., Kralova K. Potential of nanonutraceuticals in increasing immunity. Nanomaterials. 2020;10:2224. doi: 10.3390/nano10112224. PubMed DOI PMC

Kushkevych I., Kos J., Kollar P., Kralova K., Jampilek J. Activity of ring-substituted 8-hydroxyquinoline-2-carboxanilides against intestinal sulfate-reducing bacteria Desulfovibrio piger. Med. Chem. Res. 2018;27:278–284. doi: 10.1007/s00044-017-2067-7. DOI

Kushkevych I., Vitezova M., Kos J., Kollar P., Jampilek J. Effect of selected 8-hydroxyquinoline-2-carboxanilides on viability and sulfate metabolism of Desulfovibrio piger. J. Appl. Biomed. 2018;16:241–246. doi: 10.1016/j.jab.2018.01.004. DOI

Inflammatory Bowel Disease—Mayo Clinic. [(accessed on 27 November 2020)];2020 Available online: https://www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/diagnosis-treatment/drc-20353320.

Khare T., Palakurthi S.S., Shah B.M., Palakurthi S., Khare S. Natural product-based nanomedicine in treatment of inflammatory bowel disease. Int. J. Mol. Sci. 2020;21:3956. doi: 10.3390/ijms21113956. PubMed DOI PMC

Rheumatoid Arthritis—Mayo Clinic. [(accessed on 27 November 2020)];2020 Available online: https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/diagnosis-treatment/drc-20353653.

Rosman Z., Shoenfeld Y., Zandman-Goddard G. Biologic therapy for autoimmune diseases: An update. BMC Med. 2013;11:88. doi: 10.1186/1741-7015-11-88. PubMed DOI PMC

Baumgart D.C., Misery L., Naeyaert S., Taylor P.C. Biological therapies in immune-mediated inflammatory diseases: Can biosimilars reduce access inequities? Front. Pharmacol. 2019;10:279. doi: 10.3389/fphar.2019.00279. PubMed DOI PMC

Tasneem S., Liu B., Lia B., Choudhary I., Wang W. Molecular pharmacology of inflammation: Medicinal plants as anti-inflammatory agents. Pharm. Res. 2019;139:126–140. doi: 10.1016/j.phrs.2018.11.001. PubMed DOI

Jampilek J., Kos J., Kralova K. Potential of nanomaterial applications in dietary supplements and foods for special medical purposes. Nanomaterials. 2019;9:296. doi: 10.3390/nano9020296. PubMed DOI PMC

Healthline Media Understanding and Managing Chronic Inflammation. [(accessed on 27 November 2020)];2020 Available online: https://www.healthline.com/health/chronic-inflammation.

Ballerini C., Baldi G., Aldinucci A., Maggi P. Nanomaterial applications in multiple sclerosis inflamed brain. J. Neuroimmune Pharmacol. 2015;10:1–13. doi: 10.1007/s11481-015-9588-y. PubMed DOI

Patra J.K., Das G., Fraceto F.L., Campos E.V.R., del Pilar Rodriguez-Torres M., Acosta-Torres L.S., Diaz-Torres L.A., Grillo R., Swamy M.K., Sharma S., et al. Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnol. 2018;16:71. doi: 10.1186/s12951-018-0392-8. PubMed DOI PMC

Rahoui N., Jiang B., Taloub N., Huang Y.D. Spatio-temporal control strategy of drug delivery systems based nano structures. J. Control. Release. 2017;255:176–201. doi: 10.1016/j.jconrel.2017.04.003. PubMed DOI

Hofmann-Amtenbrink M., Hofmann H., Hool A., Roubert F. Nanotechnology in medicine: European research and its implications. Swiss Med. Wkl. 2014;144:w1404. doi: 10.4414/smw.2014.14044. PubMed DOI

Fornaguera C., Garcia-Celma M.J. Personalized nanomedicine: A revolution at the nanoscale. J. Pers. Med. 2017;7:12. doi: 10.3390/jpm7040012. PubMed DOI PMC

Bhatt P., Vhora I., Patil S., Amrutiya J., Bhattacharya C., Misra A., Mashru R. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. J. Control. Release. 2016;226:148–167. doi: 10.1016/j.jconrel.2016.02.008. PubMed DOI

Aminu N., Bello I., Umar N.M., Tanko N., Aminu A., Audu M.M. The influence of nanoparticulate drug delivery systems in drug therapy. J. Drug Deliv. Sci. Technol. 2020;60:101961. doi: 10.1016/j.jddst.2020.101961. DOI

Sufi S.A., Pajaniradje S., Mukherjee V., Rajagopalan R. Redox nano-architectures: Perspectives and implications in diagnosis and treatment of human diseases. Antiox. Redox Signal. 2019;30:762–785. doi: 10.1089/ars.2017.7412. PubMed DOI

Mercado N., Bhatt P., Sutariya V., Florez F.L.E., Pathak Y.V. Application of nanoparticles in treating periodontitis: Preclinical and clinical overview. In: Pathak Y., editor. Surface Modification of Nanoparticles for Targeted Drug Delivery. Springer; Cham, Switzerland: 2019. pp. 467–480.

Ulbrich W., Lamprecht A. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases. J. R. Soc. Interface. 2010;7:55–66. doi: 10.1098/rsif.2009.0285.focus. PubMed DOI PMC

Pentak D., Kozik V., Bak A., Dybal P., Sochanik A., Jampilek J. Methotrexate and cytarabine—loaded nanocarriers for multidrug cancer therapy. Spectroscopic study. Molecules. 2016;21:1689. doi: 10.3390/molecules21121689. PubMed DOI PMC

Placha D., Jampilek J. Graphenic materials for biomedical applications. Nanomaterials. 2019;9:1758. doi: 10.3390/nano9121758. PubMed DOI PMC

Jampilek J., Kralova K. Nano-antimicrobials: Activity, benefits and weaknesses. In: Ficai A., Grumezescu A.M., editors. Nanostructures for Antimicrobial Therapy. Elsevier; Amsterdam, The Netherlands: 2017. pp. 23–54.

Jampilek J., Kralova K. Application of nanobioformulations for controlled release and targeted biodistribution of drugs. In: Sharma A.K., Keservani R.K., Kesharwani R.K., editors. Nanobiomaterials: Applications in Drug Delivery. CRC Press; Warentown, NJ, USA: 2018. pp. 131–208.

Jampilek J., Kralova K. Nanotechnology based formulations for drug targeting to central nervous system. In: Keservani R.K., Sharma A.K., editors. Nanoparticulate Drug Delivery Systems. Apple Academic Press & CRC Press; Warentown, NJ, USA: 2019. pp. 151–220.

Jampilek J., Kralova K. Recent advances in lipid nanocarriers applicable in the fight against cancer. In: Grumezescu A.M., editor. Nanoarchitectonics in Biomedicine. Elsevier; Amsterdam, The Netherlands: 2019. pp. 219–294.

Jampilek J., Kralova K., Campos E.V.R., Fraceto L.F. Bio-based nanoemulsion formulations applicable in agriculture, medicine and food industry. In: Prasad R., Kumar V., Kumar M., Choudhary D.K., editors. Nanobiotechnology in Bioformulations. Springer; Cham, Germany: 2019. pp. 33–84.

Jampilek J., Kralova K. Nanoformulations—valuable tool in therapy of viral diseases attacking humans and animals. In: Rai M., Jamil B., editors. Nanotheranostic—Applications and Limitations. Springer Nature; Cham, Switzerland: 2019. pp. 137–178.

Jampilek J., Kralova K., Novak P., Novak M. Nanobiotechnology in neurodegenerative diseases. In: Rai M., Yadav A., editors. Nanobiotechnology in Neurodegenerative Diseases. Springer Nature Switzerland AG; Cham, Switzerland: 2019. pp. 65–138.

Jampilek J., Kralova K. Natural biopolymeric nanoformulations for brain drug delivery. In: Keservani R.K., Sharma A.K., Kesharwani R.K., editors. Nanocarriers for Brain Targetting: Principles and Applications. Apple Academic Press & CRC Press; Warentown, NJ, USA: 2020. pp. 131–203.

Fleige E., Quadir M.A., Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: Concepts and applications. Adv. Drug Deliv. Rev. 2012;64:866–884. doi: 10.1016/j.addr.2012.01.020. PubMed DOI

Molina M., Asadian-Birjand M., Balach J., Bergueiro J., Miceli E., Calderon M. Stimuli-responsive nanogel composites and their application in nanomedicine. Chem. Soc. Rev. 2015;44:6161–6186. doi: 10.1039/C5CS00199D. PubMed DOI

Kost B., Brzezinski M., Socka M., Basko M., Biela T. Biocompatible polymers combined with cyclodextrins: Fascinating materials for drug delivery applications. Molecules. 2020;25:3404. doi: 10.3390/molecules25153404. PubMed DOI PMC

Jampilek J., Kralova K. Impact of nanoparticles on toxigenic fungi. In: Rai M., Abd-Elsalam K.A., editors. Nanomycotoxicology—Treating Mycotoxins in Nano Way. Academic Press & Elsevier; London, UK: 2020. pp. 309–348.

Dou Y., Li C., Li L., Guo J., Zhang J. Bioresponsive drug delivery systems for the treatment of inflammatory diseases. J. Control. Release. 2020;327:641–666. doi: 10.1016/j.jconrel.2020.09.008. PubMed DOI PMC

Li F., Qin Y., Lee J., Liao H., Wang N., Davis T.P., Qiao R., Ling D. Stimuli-responsive nano-assemblies for remotely controlled drug delivery. J. Control. Release. 2020;322:566–592. doi: 10.1016/j.jconrel.2020.03.051. PubMed DOI

Kumar R., Dalvi S.V., Siril P.F. Nanoparticle-based drugs and formulations: Current status and emerging applications. ACS Appl. Nano Mater. 2020;3:4944–4961. doi: 10.1021/acsanm.0c00606. DOI

Yetisgin A.A., Cetinel S., Zuvin M., Kosar A., Kutlu O. Therapeutic Nanoparticles and Their Targeted Delivery Applications. Molecules. 2020;25:2193. doi: 10.3390/molecules25092193. PubMed DOI PMC

Saito E., Kuo R., Pearson R.M., Gohel N., Cheung B., King N.J.C., Miller S.D., Shea L.D. Designing drug-free biodegradable nanoparticles to modulate inflammatory monocytes and neutrophils for ameliorating inflammation. J. Control. Release. 2019;300:185–196. doi: 10.1016/j.jconrel.2019.02.025. PubMed DOI PMC

Cheng C.A., Deng T., Lin F.C., Cai Y., Zink J.I. Supramolecular nanomachines as stimuli-responsive gatekeepers on mesoporous silica nanoparticles for antibiotic and cancer drug delivery. Theranostics. 2019;9:3341–3364. doi: 10.7150/thno.34576. PubMed DOI PMC

Getts D.R., Shea L.D., Miller S.D., King N.J.C. Harnessing nanoparticles for immune modulation. Trends Immunol. 2015;36:419–427. doi: 10.1016/j.it.2015.05.007. PubMed DOI PMC

Chenthamara D., Subramaniam S., Ramakrishnan S.G., Krishnaswamy S., Essa M.M., Lin F.H., Qoronfleh M.W. Therapeutic efficacy of nanoparticles and routes of administration. Biomater. Res. 2019;23:1–29. doi: 10.1186/s40824-019-0166-x. PubMed DOI PMC

Esfanjani A.F., Jafari S.M. Biopolymer nano-particles and natural nano-carriers for nano-encapsulation of phenolic compounds. Colloids Surf. B Biointerfaces. 2016;146:532–543. doi: 10.1016/j.colsurfb.2016.06.053. PubMed DOI

Peng Y., Chen L., Ye S., Kang Y., Liu J., Zeng S., Yu L. Research and development of drug delivery systems based on drug transporter and nano-formulation. Asian J. Pharm. Sci. 2020;15:220–236. doi: 10.1016/j.ajps.2020.02.004. PubMed DOI PMC

Wang T., Zhang D., Sun D., Gu J. Current status of in vivo bioanalysis of nano drug delivery systems. J. Pharm. Anal. 2020;10:221–232. doi: 10.1016/j.jpha.2020.05.002. PubMed DOI PMC

Brzezinski M., Wedepohl S., Kost B., Calderon M. Nanoparticles from supramolecular polylactides overcome drug resistance of cancer cells. Eur. Polym. J. 2018;109:117–123. doi: 10.1016/j.eurpolymj.2018.08.060. DOI

Chen W.H., Yang C.X., Qiu W.X., Luo G.F., Jia H.Z., Lei Q., Wang X.Y., Liu G., Zhuo R.X., Zhang X.Z. Multifunctional Theranostic Nanoplatform for Cancer Combined Therapy Based on Gold Nanorods. Adv. Healthc. Mater. 2015;4:2247–2259. doi: 10.1002/adhm.201500453. PubMed DOI

Culen M., Rezacova A., Jampilek J., Dohnal J. Designing a dynamic dissolution method: A review of instrumental options and corresponding physiology of stomach and small intestine. J. Pharm. Sci. 2013;102:2995–3017. doi: 10.1002/jps.23494. PubMed DOI

Ghosh S., Mukherjee B., Chaudhuri S., Roy T., Mukherjee A., Sengupta S. Methotrexate Aspasomes Against Rheumatoid Arthritis: Optimized Hydrogel Loaded Liposomal Formulation with In Vivo Evaluation in Wistar Rats. AAPS PharmSciTech. 2018;19:1320–1336. doi: 10.1208/s12249-017-0939-2. PubMed DOI

Date A.A., Hanes J., Ensign L.M. Nanoparticles for oral delivery: Design, evaluation and state-of-the-art. J. Control. Release. 2016;240:504–526. doi: 10.1016/j.jconrel.2016.06.016. PubMed DOI PMC

Chen Y., Shan X., Luo C., He Z. Emerging nanoparticulate drug delivery systems of metformin. J. Pharm. Investig. 2020;50:219–230. doi: 10.1007/s40005-020-00480-1. DOI

Khan F.A., Almohazey D., Alomari M., Almofty S.A. Impact of nanoparticles on neuron biology: Current research trends. Int. J. Nanomed. 2018;13:2767–2776. doi: 10.2147/IJN.S165675. PubMed DOI PMC

Pinon-Segundo E., Ganem-Quintanar A., Alonso-Perez V., Quintanar-Guerrero D. Preparation and characterization of triclosan nanoparticles for periodontal treatment. Int. J. Pharm. 2005;294:217–232. doi: 10.1016/j.ijpharm.2004.11.010. PubMed DOI

Maghsoudnia N., Eftekhari R.B., Sohi A.N., Zamzami A., Dorkoosh F.A. Application of nano-based systems for drug delivery and targeting: A review. J. Nanopart. Res. 2020;22:245. doi: 10.1007/s11051-020-04959-8. DOI

Moulari B., Beduneau A., Pellequer Y., Lamprecht A. Nanoparticle targeting to inflamed tissues of the gastrointestinal tract. Curr. Drug Deliv. 2013;10:9–17. doi: 10.2174/1567201811310010004. PubMed DOI

Takedatsu H. Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease. World J. Gastroenterol. 2015;21:11343–11352. doi: 10.3748/wjg.v21.i40.11343. PubMed DOI PMC

Beloqui A., Coco R., Preat V. Targeting inflammatory bowel diseases by nanocarriers loaded with small and biopharmaceutical anti-inflammatory drugs. Curr. Pharm. Des. 2016;22:6192–6206. doi: 10.2174/1381612822666160211141813. PubMed DOI

Nunes R., das Neves J., Sarmento B. Nanoparticles for the regulation of intestinal inflammation: Opportunities and challenges. Nanomedicine. 2019;14:2631–2644. doi: 10.2217/nnm-2019-0191. PubMed DOI

Yang C., Merlin D. Nanoparticle-mediated drug delivery systems for the treatment of IBD: Current perspectives. Int. J. Nanomed. 2019;14:8875–8889. doi: 10.2147/IJN.S210315. PubMed DOI PMC

Zeeshan M., Ali H., Khan S., Khan S.A., Weigmann B. Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease. Int. J. Pharm. 2019;558:201–214. doi: 10.1016/j.ijpharm.2018.12.074. PubMed DOI

Zhang M., Merlin D. Nanoparticle-based oral drug delivery systems targeting the colon for treatment of ulcerative colitis. Inflamm. Bowel Dis. 2018;24:1401–1415. doi: 10.1093/ibd/izy123. PubMed DOI PMC

Khare V., Krnjic A., Frick A., Gmainer C., Asboth M., Jimenez K., Lang M., Baumgartner M., Evstatiev R., Gasche C. Mesalamine and azathioprine modulate junctional complexes and restore epithelial barrier function in intestinal inflammation. Sci. Rep. 2019;9:2842. doi: 10.1038/s41598-019-39401-0. PubMed DOI PMC

Zieba M., Chaber P., Duale K., Maksymiak M.M., Basczok M., Kowalczuk M., Adamus G. Polymeric carriers for delivery systems in the treatment of chronic periodontal disease. Polymers. 2020;12:1574. doi: 10.3390/polym12071574. PubMed DOI PMC

Maniar K.H., Jones I.A., Gopalakrishna R., Vangsness C.T. Lowering side effects of NSAID usage in osteoarthritis: Recent attempts at minimizing dosage. Expert Opin. Pharmacother. 2018;19:93–102. doi: 10.1080/14656566.2017.1414802. PubMed DOI

Chegini S.P., Varshosaz J., Taymouri S. Recent approaches for targeted drug delivery in rheumatoid arthritis diagnosis and treatment. Artif. Cell. Nanomed. Biotechnol. 2018;46:502–514. doi: 10.1080/21691401.2018.1460373. PubMed DOI

Lima A.C., Ferreira H., Reis R.L., Neves N.M. Biodegradable polymers: An update on drug delivery in bone and cartilage diseases. Expert Opin. Drug Deliv. 2019;16:795–813. doi: 10.1080/17425247.2019.1635117. PubMed DOI

Brown S., Kumar S., Sharma B. Intra-articular targeting of nanomaterials for the treatment of osteoarthritis. Acta Biomater. 2020;93:239–257. doi: 10.1016/j.actbio.2019.03.010. PubMed DOI PMC

Kesharwani D., Paliwal R., Satapathy T., Das P.S. Rheumatiod arthritis: An updated overview of latest therapy and drug delivery. J. Pharmacopunct. 2019;22:210–224. PubMed PMC

Ain Q., Zeeshan M., Khan S., Ali H. Biomimetic hydroxyapatite as potential polymeric nanocarrier for the treatment of rheumatoid arthritis. J. Biomed. Mater. Res. A. 2019;107:2595–2600. doi: 10.1002/jbm.a.36765. PubMed DOI

Qindeel M., Ullah M.H., Fakhar-Ud-Din, Ahmed N., Rehman A. Recent trends, challenges and future outlook of transdermal drug delivery systems for rheumatoid arthritis therapy. J. Control. Release. 2020;327:595–615. doi: 10.1016/j.jconrel.2020.09.016. PubMed DOI

Yokota J., Kyotani S. Influence of nanoparticle size on the skin penetration, skin retention and anti-inflammatory activity of non-steroidal anti-inflammatory drugs. J. Chin. Med. Assoc. 2019;81:511–519. doi: 10.1016/j.jcma.2018.01.008. PubMed DOI

Kim S.H., Moon J.H., Jeong S.U., Jung H.H., Park C.S., Hwang B.Y., Lee C.K. Induction of antigen-specific immune tolerance using biodegradable nanoparticles containing antigen and dexamethasone. Int. J. Nanomed. 2019;14:5229–5242. doi: 10.2147/IJN.S210546. PubMed DOI PMC

Zhang S., Ermann J., Succi M.D., Zhou A., Hamilton M.J., Cao B., Korzenik J.R., Glickman J.N., Vemula P.K., Glimcher L.H., et al. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease. Sci. Transl. Med. 2015;7:300ra128. doi: 10.1126/scitranslmed.aaa5657. PubMed DOI PMC

Assali M., Shawahna R., Dayyeh S., Shareef M., Alhimony I.A. Dexamethasone-diclofenac loaded polylactide nanoparticles: Preparation, release and anti-inflammatory activity. Eur. J. Pharm. Sci. 2018;122:179–184. doi: 10.1016/j.ejps.2018.07.012. PubMed DOI

Date A.A., Halpert G., Babu T., Ortiz J., Kanvinde P., Dimitrion P., Narayan J., Zierden H., Betageri K., Musmanno O., et al. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease. Biomaterials. 2018;185:97–105. doi: 10.1016/j.biomaterials.2018.09.005. PubMed DOI PMC

Gai X., Jiang Z., Liu M., Li Q., Wang S., Li T., Pan W., Yang X. Therapeutic Effect of a Novel Nano-Drug Delivery System on Membranous Glomerulonephritis Rat Model Induced by Cationic Bovine Serum. AAPS Pharm. Sci. Tech. 2018;19:2195–2202. doi: 10.1208/s12249-018-1034-z. PubMed DOI

Hanafy A.F., Abdalla A.M., Guda T.K., Gabr K.E., Royall P.G., Alqurshi A. Ocular anti-inflammatory activity of prednisolone acetate loaded chitosan-deoxycholate self-assembled nanoparticles. Int. J. Nanomed. 2019;14:3679–3689. doi: 10.2147/IJN.S195892. PubMed DOI PMC

Gupta R.D., Raghav N. Nano-crystalline cellulose: Preparation, modification and usage as sustained release drug delivery excipient for some non-steroidal anti-inflammatory drugs. Int. J. Biol. Macromol. 2020;147:921–930. doi: 10.1016/j.ijbiomac.2019.10.057. PubMed DOI

Kumar R., Singh A., Garg N., Siril P.F. Solid lipid nanoparticles for the controlled delivery of poorly water soluble non-steroidal anti-inflammatory drugs. Ultrason. Sonochem. 2018;40:686–696. doi: 10.1016/j.ultsonch.2017.08.018. PubMed DOI

Shah R., Eldridge D.S., Palombo E.A., Harding I.H. Microwave-assisted formulation of solid lipid nanoparticles loaded with non-steroidal anti-inflammatory drugs. Int. J. Pharm. 2016;515:543–554. doi: 10.1016/j.ijpharm.2016.10.054. PubMed DOI

Guilherme V.A., Ribeiro L.N.M., Alcantara A.C.S., Castro S.R., da Silva G.H.R., Goncalves da Silva C., Breitkreitz M.C., Clemente-Napimoga J., Macedo C.G., Abdalla H.B., et al. Improved efficacy of naproxen-loaded NLC for temporomandibular joint administration. Sci. Rep. 2019;9:11160. doi: 10.1038/s41598-019-47486-w. PubMed DOI PMC

Dalmoro A., Bochicchio S., Nasibullin S.F., Bertoncin P., Lamberti G., Barba A.A., Moustafine R.I. Polymer-lipid hybrid nanoparticles as enhanced indomethacin delivery systems. Eur. J. Pharm. Sci. 2018;121:16–28. doi: 10.1016/j.ejps.2018.05.014. PubMed DOI

Ozturk A.A., Kiyan H.T. Treatment of oxidative stress-induced pain and inflammation with dexketoprofen trometamol loaded different molecular weight chitosan nanoparticles: Formulation, characterization and anti-inflammatory activity by using in vivo HET-CAM assay. Microvasc. Res. 2020;128:103961. doi: 10.1016/j.mvr.2019.103961. PubMed DOI

Kishore N., Raja M.D., Kumar C.S., Dhanalekshmi U., Srinivasan R. Lipid carriers for delivery of celecoxib: In-vitro, in-vivo assessment of nanomedicine in rheumatoid arthritis. Eur. J. Lipid Sci. Technol. 2016;118:949–958. doi: 10.1002/ejlt.201400658. DOI

Badri W., Miladi K., Robin S., Viennet C., Nazari Q.A., Agusti G., Fessi H., Elaissari A. Polycaprolactone based nanoparticles loaded with indomethacin for anti-inflammatory therapy: From preparation to ex vivo study. Pharm. Res. 2017;34:1773–1783. doi: 10.1007/s11095-017-2166-7. PubMed DOI

Jampilek J., Brychtova K. Azone analogues: Classification, design, and transdermal penetration principles. Med. Res. Rev. 2012;32:907–947. doi: 10.1002/med.20227. PubMed DOI

Farghaly D.A., Aboelwafa A.A., Hamza M.Y., Mohamed M.I. Topical delivery of fenoprofen calcium via elastic nano-vesicular spanlastics: Optimization using experimental design and in vivo evaluation. AAPS Pharm. Sci. Tech. 2017;18:2898–2909. doi: 10.1208/s12249-017-0771-8. PubMed DOI

Madhumathi K., Rubaiya Y., Doble M., Venkateswari R., Sampath Kumar T.S. Antibacterial, anti-inflammatory, and bone-regenerative dual-drug-loaded calcium phosphate nanocarriers—in vitro and in vivo studies. Drug Deliv. Transl. Res. 2018;8:1066–1077. doi: 10.1007/s13346-018-0532-6. PubMed DOI

Liu L., Hu F., Wang H., Wu X., Shaker Eltahan A., Stanford S., Bottini N., Xiao H., Bottini M., Guo W., et al. Secreted protein acidic and rich in cysteine mediated biomimetic delivery of methotrexate by albumin-based nanomedicines for rheumatoid arthritis therapy. ACS Nano. 2019;13:5036–5048. doi: 10.1021/acsnano.9b01710. PubMed DOI

Kumar V., Leekha A., Tyagi A., Kaul A., Mishra A.K., Verma A.K. Preparation and evaluation of biopolymeric nanoparticles as drug delivery system in effective treatment of rheumatoid arthritis. Pharm. Res. 2017;34:654–667. doi: 10.1007/s11095-016-2094-y. PubMed DOI

Lima S.A., Reis S. Temperature-responsive polymeric nanospheres containing methotrexate and gold nanoparticles: A multi-drug system for theranostic in rheumatoid arthritis. Colloids Surf. B Biointerfaces. 2015;133:378–387. doi: 10.1016/j.colsurfb.2015.04.048. PubMed DOI

Barbosa A.I., Costa Lima S.A., Reis S. Development of methotrexate loaded fucoidan/chitosan nanoparticles with anti-inflammatory potential and enhanced skin permeation. Int. J. Biol. Macromol. 2019;124:1115–1122. doi: 10.1016/j.ijbiomac.2018.12.014. PubMed DOI

Ferreira M., Barreiros L., Segundo M.A., Torres T., Selores M., Costa Lima S.A., Reis S. Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: A targeted approach for psoriasis management. Colloids Surf. B Biointerfaces. 2017;159:23–29. doi: 10.1016/j.colsurfb.2017.07.080. PubMed DOI

Giulbudagian M., Yealland G., Hönzke S., Edlich A., Geisendorfer B., Kleuser B., Hedtrich S., Calderon M. Breaking the barrier—potent anti-inflammatory activity following efficient topical delivery of etanercept using thermoresponsive nanogels. Theranostics. 2018;8:450–463. doi: 10.7150/thno.21668. PubMed DOI PMC

Walsh L., Ryu J., Bock S., Koval M., Mauro T., Ross R., Desai T. Nanotopography facilitates in vivo transdermal delivery of high molecular weight therapeutics through an integrin-dependent mechanism. Nano Lett. 2015;15:2434–2441. doi: 10.1021/nl504829f. PubMed DOI PMC

Kim J.M., Kim D.H., Park H.J., Ma H.W., Park S., Son M., Ro S.Y., Hong S., Han H.K., Lim S.J., et al. Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model. J. Nanobiotechnol. 2020;18:133. doi: 10.1186/s12951-020-00693-4. PubMed DOI PMC

Pabari R.M., Mattu C., Partheeban S., Almarhoon A., Boffito M., Ciardelli G., Ramtoola Z. Novel polyurethane-based nanoparticles of infliximab to reduce inflammation in an in-vitro intestinal epithelial barrier model. Int. J. Pharm. 2019;565:533–542. doi: 10.1016/j.ijpharm.2019.05.025. PubMed DOI

Kishimoto T.K., Ferrari J.D., LaMothe R.A., Kolte P.N., Griset A.P., O’Neil C., Chan V., Browning E., Chalishazar A., Kuhlman W., et al. Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. Nat. Nanotechnol. 2016;11:890–899. doi: 10.1038/nnano.2016.135. PubMed DOI

Friedrich R.B., Coradini K., Fonseca F.N., Guterres S.S., Beck R.C.R., Pohlmann A.R. Lipid-core nanocapsules improved antiedematogenic activity of tacrolimus in adjuvant-induced arthritis model. J. Nanosci. Nanotechnol. 2016;16:1265–1274. doi: 10.1166/jnn.2016.11673. PubMed DOI

Hegazy S.K., El-Morsy Abd El-Ghany El-Sayed S., El-Saeed El-Hefnawy M. A clinical study evaluating the effects of fluvastatin on serum osteoprotegerin levels in rheumatoid arthritis patients. J. Clin. Pharmacol. 2016;56:1272–1276. doi: 10.1002/jcph.725. PubMed DOI

El Menshawe S.F., Nafady M.M., Aboud H.M., Kharshoum R.M., Elkelawy A.M.M.H., Hamad D.S. Transdermal delivery of fluvastatin sodium via tailored spanlastic nanovesicles: Mitigated Freund’s adjuvant-induced rheumatoid arthritis in rats through suppressing p38 MAPK signaling pathway. Drug Deliv. 2019;26:1140–1154. doi: 10.1080/10717544.2019.1686087. PubMed DOI PMC

De Araujo R.F., De Araujo A.A., Pessoa J.B., Freire Neto F.P., Ribeiro da Silva G., Leitao Oliveira A.L.C.S., Gomes de Carvalho T., Silva H.F.O., Eugenio M., Sant’Anna C., et al. Anti-inflammatory, analgesic and anti-tumor properties of gold nanoparticles. Pharmacol. Rep. 2017;69:119–129. doi: 10.1016/j.pharep.2016.09.017. PubMed DOI

Lautenschlager C., Schmidt C., Lehr C.M., Fischer D., Stallmach A. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur. J. Pharm. Biopharm. 2013;85:578–586. doi: 10.1016/j.ejpb.2013.09.016. PubMed DOI

Rao K., Aziz S., Roome T., Razzak A., Sikandar B., Jamali K.S., Imran M., Jabri T., Raza Shah M. Gum acacia stabilized silver nanoparticles based nano-cargo for enhanced anti-arthritic potentials of hesperidin in adjuvant induced arthritic rats. Artif. Cells Nanomed. Biotechnol. 2018;46:597–607. doi: 10.1080/21691401.2018.1431653. PubMed DOI

Rao D.S. Rheumatoid arthritis (RA) disease treatment with rutin stabilized nanoparticles. Austin J. Biotechnol. Bioeng. 2015;2:1043.

Hewlings S.J., Kalman D.S. Curcumin: A review of its’ effects on human health. Foods. 2017;6:92. doi: 10.3390/foods6100092. PubMed DOI PMC

Lee S.Y., Cho S.S., Li Y.C., Bae C.S., Park K.M., Park D.H. Anti-inflammatory effect of curcuma longa and allium hookeri co-treatment via NF-κB and COX-2 pathways. Sci. Rep. 2020;10:5718. doi: 10.1038/s41598-020-62749-7. PubMed DOI PMC

Wal P., Saraswat N., Pal R.S., Wal A., Chaubey M. A detailed insight of the anti-inflammatory effects of curcumin with the assessment of parameters, sources of ROS and associated mechanisms. Open Med. J. 2019;6:64–76. doi: 10.2174/1874220301906010064. DOI

Naksuriya O., Okonogi S., Schiffelers R.M., Hennink W.E. Curcumin nanoformulations: A review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014;35:3365–3383. doi: 10.1016/j.biomaterials.2013.12.090. PubMed DOI

Rahimi H.R., Nedaeinia R., Shamloo A.S., Nikdoust S., Oskuee R.K. Novel delivery system for natural products: Nano-curcumin formulations. Avicenna J. Phytomed. 2016;6:383–398. PubMed PMC

Karthikeyan A., Senthil N., Min T. Nanocurcumin: A promising candidate for therapeutic applications. Front. Pharmacol. 2020;11:487. doi: 10.3389/fphar.2020.00487. PubMed DOI PMC

Bonaccorso A., Gigliobianco M.R., Pellitteri R., Santonocito D., Carbone C., Di Martino P., Puglisi G., Musumeci T. Optimization of curcumin nanocrystals as promising strategy for nose-to-brain delivery application. Pharmaceutics. 2020;12:476. doi: 10.3390/pharmaceutics12050476. PubMed DOI PMC

Valizadeh H., Abdolmohammadi-Vahid S., Danshina S., Gencer M.Z., Ammari A., Sadeghi A., Roshangar L., Aslani S., Esmaeilzadeh A., Ghaebi M., et al. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int. Immunopharmacol. 2020;89:107088. doi: 10.1016/j.intimp.2020.107088. PubMed DOI PMC

Moniruzzaman M., Min T. Curcumin, curcumin nanoparticles and curcumin nanospheres: A review on their pharmacodynamics based on monogastric farm animal, poultry and fish nutrition. Pharmaceutics. 2020;12:447. doi: 10.3390/pharmaceutics12050447. PubMed DOI PMC

Del Prado-Audelo M.L., Caballero-Floran I.H., Meza-Toledo J.A., Mendoza-Munoz N., Gonzalez-Torres M., Floran B., Cortes H., Leyva-Gomez G. Formulations of curcumin nanoparticles for brain diseases. Biomolecules. 2019;9:56. doi: 10.3390/biom9020056. PubMed DOI PMC

Yavarpour-Bali H., Ghasemi-Kasman M., Pirzadeh M. Curcumin-loaded nanoparticles: A novel therapeutic strategy in treatment of central nervous system disorders. Int. J. Nanomed. 2019;14:4449–4460. doi: 10.2147/IJN.S208332. PubMed DOI PMC

Ubeyitogullari A., Ciftci O.N. A novel and green nanoparticle formation approach to forming low-crystallinity curcumin nanoparticles to improve curcumin’s bioaccessibility. Sci. Rep. 2019;9:19112. doi: 10.1038/s41598-019-55619-4. PubMed DOI PMC

Coradini K., Friedrich R.B., Fonseca F.N., Vencato M.S., Andrade D.F., Oliveira C.M., Battistel A.P., Guterres S.S., da Rocha M.I., Pohlmann A.R., et al. A novel approach to arthritis treatment based on resveratrol and curcumin co-encapsulated in lipid-core nanocapsules: In-vivo studies. Eur. J. Pharm. Sci. 2015;78:163–170. doi: 10.1016/j.ejps.2015.07.012. PubMed DOI

Kakkar V., Kaur I.P., Kaur A.P., Saini K., Singh K.K. Topical delivery of tetrahydrocurcumin lipid nanoparticles effectively inhibits skin inflammation: In vitro and in vivo study. Drug Dev. Ind. Pharm. 2018;44:1701–1712. doi: 10.1080/03639045.2018.1492607. PubMed DOI

Yang C., Zhang M., Lama S., Wang L., Merlin D. Natural-lipid nanoparticle-based therapeutic approach to deliver 6-shogaol and its metabolites M2 and M13 to the colon to treat ulcerative colitis. J. Control. Release. 2020;323:293–310. doi: 10.1016/j.jconrel.2020.04.032. PubMed DOI PMC

Gai W., Hao X., Zhao J., Wang L., Liu J., Jiang H., Jin H., Liu G., Feng Y. Delivery of benzoylaconitine using biodegradable nanoparticles to suppress inflammation via regulating NF-κB signaling. Colloids Surf. B Biointerfaces. 2020;191:1–10. doi: 10.1016/j.colsurfb.2020.110980. PubMed DOI

Chen S.R., Dai Y., Zhao J., Lin L., Wang Y., Wang Y. A mechanistic overview of triptolide and celastrol, natural products from Tripterygium wilfordii Hook F. Front. Pharmacol. 2018;9:104. doi: 10.3389/fphar.2018.00104. PubMed DOI PMC

Zhang L., Chang J., Zhao Y., Xu H., Wang T., Xing L., Wang Y., Liang Q. Fabrication of a triptolide-loaded and poly-γ-glutamic acid-based amphiphilic nanoparticle for the treatment of rheumatoid arthritis. Int. J. Nanomed. 2018;13:2051–2064. doi: 10.2147/IJN.S151233. PubMed DOI PMC

Land W.G. Damage-Associated Molecular Patterns in Human Diseases. Springer Nature; Cham, Switzerland: 2018. Volume 1: Injury-Induced Innate Immune Responses.

Deng Z., Rong Y., Teng Y., Mu J., Zhuang X., Tseng M., Samykutty A., Zhang L., Yan J., Miller D., et al. Broccoli-derived nanoparticle inhibits mouse colitis by activating dendritic cell AMP-activated protein kinase. Mol. Ther. 2017;25:1641–1654. doi: 10.1016/j.ymthe.2017.01.025. PubMed DOI PMC

Vijay K. Toll-like receptors in immunity and inflammatory diseases: Past, present, and future. Int. Immunopharmacol. 2018;59:391–412. doi: 10.1016/j.intimp.2018.03.002. PubMed DOI PMC

Gao W., Wang Y., Xiong Y., Sun L., Wang L., Wang K., Lu H.Y., Bao A., Turvey S.E., Li Q., et al. Size-dependent anti-inflammatory activity of a peptide-gold nanoparticle hybrid in vitro and in a mouse model of acute lung injury. Acta Biomater. 2019;85:203–217. doi: 10.1016/j.actbio.2018.12.046. PubMed DOI PMC

Fukata T., Mizushima T., Nishimura J., Okuzaki D., Wu X., Hirose H., Yokoyama Y., Kubota Y., Nagata K., Tsujimura N., et al. The supercarbonate apatite-microrna complex inhibits dextran sodium sulfate-induced colitis. Mol. Ther. Nucleic Acids. 2018;12:658–671. doi: 10.1016/j.omtn.2018.07.007. PubMed DOI PMC

Uemura Y., Naoi T., Kanai Y., Kobayashi K. The efficiency of lipid nanoparticles with an original cationic lipid as a siRNA delivery system for macrophages and dendritic cells. Pharm. Dev. Technol. 2019;24:263–268. doi: 10.1080/10837450.2018.1469149. PubMed DOI

Anticancer Applications of Essential Oils Formulated into Lipid-Based Delivery Nanosystems

Advances in Biologically Applicable Graphene-Based 2D Nanomaterials

Advances in Nanostructures for Antimicrobial Therapy

Advances in Use of Nanomaterials for Musculoskeletal Regeneration

Targeting phytoprotection in the COVID-19-induced lung damage and associated systemic effects-the evidence-based 3PM proposition to mitigate individual risks

Advances in Drug Delivery Nanosystems Using Graphene-Based Materials and Carbon Nanotubes